Dry Powder Inhalers Segment to Hold Major Respiratory Inhalers Market Share During 2022–2028
According to our new research study on "Respiratory Inhalers Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type, Technology, and Disease Indication," the market is expected to grow from US$ 31,144.56 million in 2022 to US$ 43,446.19 million by 2028; it is estimated to record a CAGR of 5.7% from 2022 to 2028. The report highlights the trends and drivers prevailing in the market.
Based on product type, the respiratory inhalers market is segmented nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment is further bifurcated into multi-dose dry powder inhalers and single-dose dry powder inhalers. The metered dose inhalers (MDI) segment is further divided into pressured metered dose inhalers and connected metered dose inhalers. The nebulizers segment is subsegmented into compressed air nebulizers, mesh air nebulizers, and ultrasonic air nebulizers. In 2022, the dry powder inhalers segment accounted for the largest market share. However, the metered dose inhalers (MDI) segment is anticipated to register the highest CAGR during the forecast period. Unlike other inhalers that deliver a puff of medicine, these inhalers hold the medicine as a dry powder. As dry powder inhalers contain a powder formulation, the patient needs to inhale fast and deep to get the medicine into the lungs. The formulation consists of an ordered mixture of micronized drugs and larger carrier lactose particles that are required to improve powder flow properties. The patient's inhalation through the device is used to disperse the powder and to ensure that some parts of the dose are carried into the lungs. Dry powder inhalers are clinically appropriate and cost-effective alternatives.
Respiratory Inhalers Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type [Nebulizers, Metered Dose Inhalers (MDI), and Dry Powder Inhalers], Technology (Manually Operated Inhalers and Digitally Operated Inhalers), and Disease Indication (Asthma, COPD, Pulmonary Arterial Hypertension, and Others)
Respiratory Inhalers Market Size & Growth | Statistics Report 2028
Download Free Sample
Based on disease indication, the respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period. Asthma is a respiratory condition in which the patient's airway swells and becomes narrow and sometimes produces extra mucus. This makes breathing difficult and triggers coughing. It is a long-term condition and noncommunicable disease affecting children and adults. Asthma is often underdiagnosed and under-treated, particularly in low- and middle-income countries. People suffering from under-treated asthma also experience sleep disturbance, tiredness during the day, and poor concentration. Asthma cannot be cured, but good management with inhaled medications can control the disease and enable people with asthma to enjoy a normal, active life. According to the Global Asthma Report New Zealand 2018, globally, asthma is ranked 16th among the leading causes of years lived with disability and 28th among the leading causes of burden of disease, as measured by disability-adjusted life years. Approximately 300 million people have asthma across the globe, and it is likely that by 2025 a further 100 million may be affected. According to the Asthma and Allergy Foundation of America, approximately 25 million people in the US are suffering from asthma, and out of it, ~20 million people are adults aged above 18 years. To treat asthma, inhalers are generally prescribed. Thus, the rising prevalence of asthma is fueling the demand for respiratory inhalers.
Impact of COVID-19 Pandemic on Respiratory Inhalers Market
The rising number of COVID-19 patients led to an overall positively impacted on the respiratory inhalers market. COVID-19 is a respiratory system infection that can rapidly cause pneumonia-like symptoms and chest infections. This may lead to poor health conditions for the patient. During the COVID-19 pandemic, respiratory inhaler providers were encouraged to increase manufacturing as COVID-19 affects the functioning of the lungs. Inhaled corticosteroids are beneficial in the treatment of COVID-19, as they reduce the expression of key proteins that are involved in the entry of SARS-CoV-2 into host cells. Inhaled corticosteroids have also been shown to cause the downregulation of COVID-19 genes. For instance, ciclesonide is a potential treatment option for COVID-19 patients. In vitro, ciclesonide has been shown to have antiviral properties against COVID-19 and block COVID-19 viral replication. This use of corticosteroids for the treatment of COVID-19 is fueling the growth of the respiratory inhalers market.
AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd.; GSK Plc; Koninklijke Philips NV; OMRON Corp; PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc. are among the several players engaged in addressing the growing demands for respiratory inhalers.
The report segments the respiratory inhalers market as follows:
The respiratory inhalers market is segmented on the basis of product type, technology, disease indication, and geography. Based on product type, the respiratory inhalers market is segmented nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment is further bifurcated into multi-dose dry powder inhalers and single-dose dry powder inhalers. The metered dose inhalers (MDI) segment is further divided into pressured metered dose inhalers and connected metered dose inhalers. The nebulizers segment is subsegmented into compressed air nebulizers, mesh air nebulizers, and ultrasonic air nebulizers. Based on technology, the respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. Based on disease indication, the respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. Based on geography, the respiratory inhalers market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Netherlands, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, Thailand, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com